131 related articles for article (PubMed ID: 9224383)
1. Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.
Gotoh A; Kao C; Ko SC; Hamada K; Liu TJ; Chung LW
J Urol; 1997 Aug; 158(2):636-41. PubMed ID: 9224383
[TBL] [Abstract][Full Text] [Related]
2. p21WAF1/CIP1 is more effective than p53 in growth suppression of mouse renal carcinoma cell line Renca in vitro and in vivo.
Kralj M; Pavelić J
J Cancer Res Clin Oncol; 2003 Aug; 129(8):463-71. PubMed ID: 12884025
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy of malignant glioma cells with 2-5A-antisense telomerase RNA and recombinant adenovirus p53.
Komata T; Kondo Y; Koga S; Ko SC; Chung LW; Kondo S
Gene Ther; 2000 Dec; 7(24):2071-9. PubMed ID: 11223987
[TBL] [Abstract][Full Text] [Related]
4. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer.
Eastham JA; Hall SJ; Sehgal I; Wang J; Timme TL; Yang G; Connell-Crowley L; Elledge SJ; Zhang WW; Harper JW
Cancer Res; 1995 Nov; 55(22):5151-5. PubMed ID: 7585563
[TBL] [Abstract][Full Text] [Related]
5. Adenoviral-mediated gene therapy with Ad5CMVp53 and Ad5CMVp21 in combination with standard therapies in human breast cancer cell lines.
Parker LP; Wolf JK; Price JE
Ann Clin Lab Sci; 2000 Oct; 30(4):395-405. PubMed ID: 11045764
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic effects of Ad5CMV-p53 expression in two human nasopharyngeal carcinoma cell lines.
Li JH; Li P; Klamut H; Liu FF
Clin Cancer Res; 1997 Apr; 3(4):507-14. PubMed ID: 9815713
[TBL] [Abstract][Full Text] [Related]
7. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells.
Sasaki R; Shirakawa T; Zhang ZJ; Tamekane A; Matsumoto A; Sugimura K; Matsuo M; Kamidono S; Gotoh A
Int J Radiat Oncol Biol Phys; 2001 Dec; 51(5):1336-45. PubMed ID: 11728695
[TBL] [Abstract][Full Text] [Related]
8. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model.
Ko SC; Gotoh A; Thalmann GN; Zhau HE; Johnston DA; Zhang WW; Kao C; Chung LW
Hum Gene Ther; 1996 Sep; 7(14):1683-91. PubMed ID: 8886839
[TBL] [Abstract][Full Text] [Related]
9. The growth inhibitory effect of p21 adenovirus on androgen-dependent and -independent human prostate cancer cells.
Gotoh A; Shirakawa T; Wada Y; Fujisawa M; Okada H; Kamidono S; Hamada K
BJU Int; 2003 Aug; 92(3):314-8. PubMed ID: 12887490
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.
Lang FF; Yung WK; Raju U; Libunao F; Terry NH; Tofilon PJ
J Neurosurg; 1998 Jul; 89(1):125-32. PubMed ID: 9647183
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for bladder cancer using adenoviral vector.
Wada Y; Gotoh A; Shirakawa T; Hamada K; Kamidono S
Mol Urol; 2001; 5(2):47-52. PubMed ID: 11690547
[TBL] [Abstract][Full Text] [Related]
12. In vitro growth suppression by adenoviral transduction of p21 and p16 in squamous cell carcinoma of the head and neck: a research model for combination gene therapy.
Mobley SR; Liu TJ; Hudson JM; Clayman GL
Arch Otolaryngol Head Neck Surg; 1998 Jan; 124(1):88-92. PubMed ID: 9440786
[TBL] [Abstract][Full Text] [Related]
13. Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer.
Eastham JA; Grafton W; Martin CM; Williams BJ
J Urol; 2000 Sep; 164(3 Pt 1):814-9. PubMed ID: 10953161
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation.
Srivastava S; Katayose D; Tong YA; Craig CR; McLeod DG; Moul JW; Cowan KH; Seth P
Urology; 1995 Dec; 46(6):843-8. PubMed ID: 7502427
[TBL] [Abstract][Full Text] [Related]
15. The effects of combining ionizing radiation and adenoviral p53 therapy in nasopharyngeal carcinoma.
Li JH; Lax SA; Kim J; Klamut H; Liu FF
Int J Radiat Oncol Biol Phys; 1999 Feb; 43(3):607-16. PubMed ID: 10078646
[TBL] [Abstract][Full Text] [Related]
16. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus.
Zhang WW; Fang X; Mazur W; French BA; Georges RN; Roth JA
Cancer Gene Ther; 1994 Mar; 1(1):5-13. PubMed ID: 7621238
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for head and neck cancer. Comparing the tumor suppressor gene p53 and a cell cycle regulator WAF1/CIP1 (p21).
Clayman GL; Liu TJ; Overholt SM; Mobley SR; Wang M; Janot F; Goepfert H
Arch Otolaryngol Head Neck Surg; 1996 May; 122(5):489-93. PubMed ID: 8615965
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antitumor effect of combined use of adenoviral-mediated p53 gene transfer and antisense oligodeoxynucleotide targeting clusterin gene in an androgen-independent human prostate cancer model.
Yamanaka K; Gleave ME; Hara I; Muramaki M; Miyake H
Mol Cancer Ther; 2005 Feb; 4(2):187-95. PubMed ID: 15713890
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of Ad5CMV-p53 in vitro and in vivo.
Zhang WW; Alemany R; Wang J; Koch PE; Ordonez NG; Roth JA
Hum Gene Ther; 1995 Feb; 6(2):155-64. PubMed ID: 7734516
[TBL] [Abstract][Full Text] [Related]
20. Activation of p53/p21Waf1/Cip1 pathway by 5-aza-2'-deoxycytidine inhibits cell proliferation, induces pro-apoptotic genes and mitogen-activated protein kinases in human prostate cancer cells.
Pulukuri SM; Rao JS
Int J Oncol; 2005 Apr; 26(4):863-71. PubMed ID: 15753979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
